Immunosuppressive Agents for the Prevention of Transplantation Rejection
Pulmonary, Bone, Vitamins and Autocoid Therapeutic Agents
Published Online: 15 SEP 2010
Copyright © 2003 by John Wiley & Sons, Inc. All rights reserved.
Burger's Medicinal Chemistry, Drug Discovery and Development
How to Cite
Pitts, W. J. 2010. Immunosuppressive Agents for the Prevention of Transplantation Rejection. Burger's Medicinal Chemistry, Drug Discovery and Development. 983–1063.
- Published Online: 15 SEP 2010
This chapter will focus on “small” molecule therapeutics that demonstrate useful immunosuppressant activity including established classes such as calcineurin inhibitors (cyclosporin A and tacrolimus), mTOR (mammalian target of rapamycin) agents (sirolimus, everolimus), and antiproliferative/antimetabolite agents (azathioprine, mycophenolic acid derivatives). This chapter will also introduce some agents with newer pharmacology mechanisms such as sphingosine receptor modulation (FTY720), inhibition of JAK3 (CP-690,550), and inhibition of PKC θ (AEB071). Other agents useful in organ transplantation including glucocorticoids (such as prednisone and dexamethasone), nitrogen mustards (such as cyclophosphamide), and biologic agents (such as muromonab-CD3, basiliximab, and daclizumab) are discussed elsewhere.